References
- van der Hilst JC. Recent insights into the pathogenesis of type AA amyloidosis. ScientificWorld Journal. 2011;11:641–50.
- Real de Asua D, Costa R, Galvan JM, Filigheddu MT, Trujillo D, Cadinanos J. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014;6:369–77.
- Kucuk A, Gezer IA, Ucar R, Karahan AY. Familial Mediterranean fever. Acta Med. 2014;57(3):97–104.
- Berkun Y, Eisenstein EM. Diagnostic criteria of familial Mediterranean fever. Autoimmun Rev. 2014;13(4–5):388–90.
- Shohat M, Halpern GJ. Familial Mediterranean fever–a review. Genet Med. 2011;13(6):487–98.
- van der Hilst J, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75–80.
- Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N. Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol. 2016;31(4):633–40.
- Hawkins PN. Amyloidosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 6th ed. Philadelphia: Elsevier; 2015. p. 1406–14.
- Sayed RH, Hawkins PN, Lachmann HJ. Emerging treatments for amyloidosis. Kidney Int. 2015;87(3):516–26.
- Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7(1):64–9.
- Koga T, Migita K, Kawakami A. Biologic therapy in familial Mediterranean fever. Mod Rheumatol. 2016;26(5):637–41.
- Laskari K, Boura P, Dalekos GN, Garyfallos A, Karokis D, Pikazis D, et al. Longterm beneficial effect of canakinumab in colchicine-resistant familial Mediterranean fever. J Rheumatol. 2017;44(1):102–9.
- Ozcakar ZB, Ozdel S, Yilmaz S, Kurt-Sukur ED, Ekim M, Yalcinkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol. 2016;35(2):441–6.
- Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial Mediterranean fever. Mod Rheumatol 2017;27:350–55.
- Scarpioni R, Rigante D, Cantarini L, Ricardi M, Albertazzi V, Melfa L, et al. Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1beta monoclonal antibody canakinumab. Clin Rheumatol. 2015;34(7):1311–16.
- Stankovic Stojanovic K, Delmas Y, Torres PU, Peltier J, Pelle G, Jeru I, et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant. 2012;27(5):1898–901.